Kyrgyzstan vs Latvia: Share of the population living with HIV receiving antiretroviral therapy
Kyrgyzstan
52.5%
in 2024
Latvia
52.4%
in 2024
Kyrgyzstan rank
121st
Latvia rank
122nd
Share of the population living with HIV receiving antiretroviral therapy over time
- Kyrgyzstan
- Latvia
How they compare
Kyrgyzstan currently reports 52.5% against 52.4% in Latvia, a difference of 0.1%.
The two have swapped places 5 times across 27 shared years of data; in 1998 it was Latvia ahead.
Kyrgyzstan ranks 121st and Latvia ranks 122nd of 149 countries.
Across the 4 decades both report, Kyrgyzstan averaged higher in 1 and Latvia in 2.
Head to head by decade
| Decade | Kyrgyzstan | Latvia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 2.0% | 3.2% | 1.2% | Latvia |
| 2010s | 24.6% | 22.0% | 2.6% | Kyrgyzstan |
| 2020s | 47.5% | 50.0% | 2.4% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Kyrgyzstan or Latvia?
- Kyrgyzstan, at 52.5% against 52.4% in Latvia as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Kyrgyzstan and Latvia?
- 0.1%, with Kyrgyzstan ahead.
- How many years of comparable data are there for Kyrgyzstan and Latvia?
- 27 years are reported by both, from 1998 to 2024.
- How do Kyrgyzstan and Latvia rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Kyrgyzstan ranks 121st and Latvia ranks 122nd of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.